Erratum to “A Randomised Controlled Trial of Fesoterodine in Subjects With Overactive Bladder and Suboptimal Response to Tolterodine Extended Release: Results From the AFTER Study” [Eur Urol Suppl 2013;2012:e740]

Subjects and methods: Subjects aged 18 y with selfreported OAB symptoms for 6 months, at least ‘‘some moderate problems’’ on the Patient Perception of Bladder Control (PPBC), 8 micturitions and 2 and <15 urgency urinary incontinence (UUI) episodes per 24 h on 3-day diary entered a 2-week, open-label run-in with tolterodine ER 4 mg. Suboptimal responders ( 50% decrease in UUI episodes during the run-in) were randomized to PBO (n = 320) or FESO (n = 308; 4 mg for 1 wk, 8 mg for wk 2– 12) once daily. Subjects completed 3-day bladder diaries and the PPBC, Urgency Perception Scale (UPS), and Overactive Bladder Questionnaire (OAB-q) at baseline and